drugset / Trial / NCT07548177

Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma

NCT07548177

Phase 2 Recruiting 33 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).

Timeline

Start
2026-04-02
Primary completion
2027-11
Completion
2028-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Benmelstobart Monoclonal antibody
Subject Catequentinib Small molecule